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Abstract
Background: It remains unclear whether the natural course of human immunodeficiency virus (HIV) differs in subjects infected
through injecting drug use (IDU) and no data have been published from low- or middle-income countries. We addressed this
question in an urban cohort in Indonesia, which is experiencing a rapidly growing HIV epidemic strongly driven by IDU.
Methods: All antiretroviral treatment (ART) naı¨ve HIV-positive patients who had at least two subsequent CD4 cell counts
available before starting ART were included in this study. We examined the association between IDU and CD4 cell decline using a
linear mixed model, with adjustment for possible confounders such as HIV viral load and hepatitis C antibodies.
Results: Among 284 HIV-positive ART naı¨ve patients, the majority were male (56%) with a history of IDU (79% among men).
People with a history of IDU had a statistically significant faster decline in CD4 cells (pB0.001). Based on our data, patients with
a history of IDU would have an average 33% decline in CD4 cells after one year without ART, compared with a 22% decline
among non-users. At two years, the decline would average 66 and 40%, respectively. No other factor was significantly associated
with CD4 cell decline.
Conclusions: We show that a history of IDU is associated with a more rapid CD4 cell natural decline among HIV-positive
individuals in Indonesia. These findings have implications for monitoring ART naı¨ve patients with a history of IDU and for starting
ART in this group.
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Introduction
Injecting drug use (IDU) is responsible for human immuno-
deficiency virus (HIV) infections in 10% of all cases world-
wide, and 30% of cases outside Africa [1]. IDU is not only a
risk factor for HIV transmission but it may also change the
natural course of HIV infection, for instance because of co-
infections and/or nutritional deficiencies. In addition, heroin
and other opioids have immune-modulating effects, which
might alter the progression of HIV infection and/or suscept-
ibility to infections [27].
Epidemiological studies looking at the association between
IDU and the natural course of HIV infection have shown
contradictory results [3,813]. Most studies used clinical
endpoints, such as mortality and AIDS-free survival, and
were conducted in high-income countries, mostly among
Caucasian subjects [812]. However, factors unrelated to HIV
infection may significantly skew the relation between IDU
and AIDS-free survival. One such factor is mortality not
related to HIV, which is usually higher among individuals
injecting drugs [1416]. Actually, various studies have shown
that overdose and suicide rather than opportunistic infec-
tions are the main cause of death in HIV-positive drug users
[17]. Furthermore, differences in the occurrence of AIDS
defining illnesses, for example, Kaposi sarcoma, may also
affect the association between risk group and AIDS-free
survival [9].
HIV reduces the number of CD4 T-lymphocytes (CD4
cells), thereby compromising cellular immunity. As such,
the number of circulating CD4 cells is the primary marker
for immunodeficiency in HIV-positive patients. Therefore, we
determined the association between IDU and the natural
decline of CD4 cells in HIV-positive ART naı¨ve patients. The
study was performed in a patient cohort in Indonesia, which
has a rapidly growing HIV epidemic, largely driven by IDU
[18]. To our knowledge, this is the first study addressing this
issue in a low- or middle-income country.
Methods
Setting and study population
This study was embedded in a five-year programme (2006
11) called ‘‘IMPACT’’, aimed at improving prevention, control
and treatment of HIV among injecting drug users in West
Java, Indonesia [18]. IMPACT has helped establish patient
care in three clinics in Bandung, the capital of West Java
(40 million people): a teaching hospital, a methadone clinic,
and a prison clinic. In these clinics, people with and without
a history of IDU, who are at risk for HIV infection or who
present with signs and symptoms suggesting HIV/AIDS are
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counselled and tested for HIV. All testing is voluntary and
informed consent is obtained from all study participants. HIV-
positive patients are characterized and followed prospec-
tively in a cohort study, which has been approved by the
Health Research Ethics Committee at the Faculty of Medicine
of Padjadjaran University/Dr. Hasan Sadikin General Hospital
in Bandung, Indonesia. Data on demographic factors, history
of IDU, co-morbidity, self-reported tuberculosis treatment
and history of antiretroviral treatment (ART) are collected
through interview with standard questionnaires. Laboratory
examinations include CD4 cell measurement at baseline and
fixed time points afterwards. Patients are seen by a doctor
every 36 months if not on ART, and more frequently when
ART is initiated. At the time of this study, ART was indicated
in Indonesia for patients presenting with WHO clinical stage
IV or a CD4 cell countB200 cells/ml in accordance with WHO
guidelines from 2006. Since 2004, ART can be accessed free
of charge in Indonesia.
Data analysis and statistics
In this study, we selected all adults (]16 years) presenting
with HIV infection between August 2007 and August 2011,
who had not yet been exposed to ART. To determine the
association between IDU and the natural decline of CD4 cells
over time, we included all patients who had two or more
CD4 cell counts measured at least one month apart, with all
measurements done before the start of ART.We used a linear
mixed model to describe the decline of CD4 cells over time
and to determine the effect association with IDU. To meet all
criteria, we transformed all CD4 cell counts to the log scale,
which enabled us to interpret the results of the mixed
models as a relative change in CD4 cells after anti-logarithmic
transformation. The dependent variable in our final model
was the log (CD4 cells) at a certain time point. The inde-
pendent variables were a constant estimate, time since
baseline in months, IDU, and a quadratic interaction term
between IDU and months. In addition, the model used a
random intercept and random slope based on time since
baseline. The model with the best fit was chosen, based on
the likelihood-ratio test and Akaike information criterion
(AIC) (the model with lowest AIC has the best fit). In addition,
we examined possible confounders in the final model, such
as age, gender, candida infection, hepatitis C virus (HCV)
antibodies and HIV viral load. Each variable was added to
the final model to examine whether it was associated with
the CD4 cell decline or whether it was a confounder for the
association with IDU. These models were compared using
AIC. HCV viral loads were tested with RT-PCR in a selec-
tion of HCV antibody-positive individuals to distinguish
currently active and previous (cleared) HCV infection. All
statistical analyses were done using STATA statistical software
(version 12.0).
Results
From a total of 1500 HIV-positive ART naı¨ve individuals, 284
met the inclusion criteria; 145 out of 743 (19.5%) individuals
with a history of IDU and 123 out of 608 (20.2%) without. The
majority were male (56%) with a history of IDU (79% among
men) (Table 1). More than half (53.8%) of all patients were
infected with HCV, and this was 89.6% among those with a
history of IDU. Patients with and without a history of IDU had
similar first CD4 cell counts (p0.945) and similar average
time between subsequent measurements (197 and 218 days,
respectively; p0.173). The total follow-up time between
the first and last CD4 cell count before initiating ART was 379
days, which was not statistically different between those with
and without a history of IDU (p0.614).
Almost half of the patients (49.3%) had two serial CD4 cell
counts, 20.4% had three CD4 cell counts, and 16.6% had four
CD4 cell counts. The remainder (13.7%) had more than five
CD4 cell counts, with a maximum of 13 CD4 cell counts. The
number of serial CD4 cell counts was similar between people
with and without a history of IDU (p0.803). The median
CD4 cell count at baseline differed slightly with the number
of serial CD4 cell counts available (324 cells/ml for two, 306
cells/ml for three, 407 cells/ml for four and 380 cells/ml for five
or more serial CD4 cell counts; p0.008).
Table 1. Characteristics of all HIV-positive patients with at least two subsequent CD4 cell counts without ART (N284)
Variable
Total population
N284
% (n/N)
Without a history of IDU
N123
% (n/N)
With a history of IDU
N145
% (n/N)
Male 56.0 (159/284) 26.0 (32/123) 83.4 (121/145)
Senior high school or university 85.5 (194/227) 76.7 (92/120) 96.9 (94/97)
History of IDU 54.1 (145/268) n.a. n.a.
Hepatitis C infection 53.8 (135/251) 9.7 (10/103) 89.6 (121/135)
Candida infection 10.7 (22/206) 5.4 (6/111) 18.2 (16/88)
Median (IQR) Median (IQR) Median (IQR)
Age (years) 28 (2631) 27 (3135) 28 (2631)
Haemoglobin (g/dl) 13.7 (12.315.1) 12.8 (11.813.9) 14.5 (13.515.6)
CD4 cell count (cells/ml) 336 (237459) 336 (249444) 337 (222493)
HIV viral load (log (copies/ml)) 3.47 (2.854.06) 3.46 (2.463.80) 3.64 (3.014.38)
Characteristics of the study population according to history of IDU. All variables were measured at baseline.
N, number of patients; IQR, interquartile range; IDU, injecting drug use.
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The natural progression of CD4 cells in HIV-positive ART
naı¨ve patients could best be described with a model including
CD4 cell count at baseline, IDU and time between the CD4
cell counts (Table 2). The final model was significantly better
than a model without IDU (likelihood-ratio test x2 47.3
pB0.001). In this final model, the influence of IDU on the
decline in CD4 cells was taken into account as a quadratic
factor, which fit significantly better than the model without
this quadratic factor (likelihood-ratio test x248.3,
pB0.001). In addition, we added a random slope to allow
differences between subjects within the model (likelihood-
ratio test x2609.9, pB0.001).
The estimates in Table 2 can be interpreted as relative
change in CD4 cells with each unit increase in the variable;
this means that the decline in CD4 cells can be noted as
110estimate. This translates in an average decline in CD4 cells
of 2.1% per month among all HIV-positive ART naı¨ve patients
(1100.0093). In addition, those with a history of IDU have
an additional decline in CD4 cells of 0.09% decrease per
month2. Based on our data, patients with a history of IDU
would have an average 33% decline in CD4 cells after one
year without ART, compared with a 22% decline among non-
users. At two years, the decline would average 66 and 40%,
respectively (Figure 1). Based on the model, the predicted
CD4 cell decline after one year would be from 600 to 387
cells/ml for subjects with a history of IDU, and from 600 to
455 cells/ml for those without a history of IDU. After two
years without ART, the predicted CD4 cell count in this model
would be 196 cells/ml for those with a history of IDU, and 351
cells/ml for those without a history of IDU (Figure 1).
Our model includes a random intercept and random slope
for all individuals used to build this model. Figure 2 shows
the fitted and observed values of all subjects with at least
five CD4 cell measurements.
We also examined if this association could be explained by
confounding. However, neither plasma HIV-RNA, gender, age,
candidiasis and HCV infection could explain the association
between IDU and CD4 cell decline (Table 3). Adding these
variables, independently or combined, did not improve the
overall fit of the model, as shown by the AIC, or alter the
estimate of IDU (Table 3). HCV-status in our study was based
on serological testing, which correlated relatively well
with circulating HCV virus measured with PCR; among 70
Table 2. Estimated parameters of the final mixed model
describing the course CD4 cell decline in ART naı¨ve HIV-positive
patients (n268)
Variable Estimate (95% CI) p
Constant 0.0964 (0.0306; 0.1623) 0.004
Baseline CD4
cell count*
0.9623 (0.9364; 0.9882) B0.001
IDU 0.0083 (0.0287; 0.0121) 0.427
Months 0.0093 (0.0133; 0.0054) B0.001
IDU*months2 0.0004 (0.0005; 0.0003) B0.001
Random effects
parameters
sd (months) 0.0287
sd (constant) 3.42 e13
*All CD4 cell counts were transformed to log scale.
Months are the number of months since first CD4 cell count.
Months2 is a quadratic term of time in months, to account for non-
linear effects of time on CD4 cell decline. IDU is taken into the model
as baseline variable to determine effect on the intercept and as
interaction with months to examine the effect of IDU on the slope.
This model with IDU fit better than the model without IDU:
likelihood-ratio test x247.3; pB0.001.
ART, antiretroviral treatment; CI, confidence interval; IDU, injecting
drug use; sd, standard deviation.
Figure 1. The predicted average decline in CD4 cells of HIV-positive ART naı¨ve patients for people without (grey) and with (black) a history
of injecting drug use (IDU). The 95% confidence intervals are given for people without (grey shaded area) and with (black dashed lines)
a history of IDU.
The CD4 cells were predicted with the following model: Log (CD4 cells)0.09640.9623*log (CD4 cells baseline)  0.0093*months 
0.0083*IDU  0.0004 IDU*months2 (Table 2).
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individuals with HCV antibodies, 59 (84.4%) had a positive
plasma HCV-RNA.
Discussion
In this study, we show that IDU is associated with a more
rapid decline of CD4 cells among ART naı¨ve HIV-positive
patients in Indonesia. It should be noted that individuals
with a history of IDU in our cohort are not from a lower or
impoverished background that might affect disease progres-
sion; most had senior high school or university education.
Instead, we suspect that the faster decline in CD4 cells
among injecting drug users can be explained by biological
Figure 2. Natural CD4 cell decline of HIV-positive ART naı¨ve patients, with observed (grey) and fitted (black) values for people without
(A) and with (B) a history of injecting drug use (IDU). All subjects with at least five CD4 cell counts are shown.
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factors, such as a direct effect of opioids, a difference in
tropism or virulence of HIV virus transmitted via IDU, or
underlying conditions such as hepatitis C virus. Irrespective
of the exact mechanism, our findings indicate that HIV
disease progression should be monitored carefully in inject-
ing drug users.
We used CD4 cell decline as an accurate and meaningful
parameter reflecting the natural course of HIV infection.
Previous studies on the effect of IDU used clinical endpoints,
which can be very different between low- and high-income
countries [812]. In industrialized countries, violence and
suicide are important causes of death among people who
inject drugs, while in low-income countries tuberculosis is
more prevalent [19]. In addition, the type of drug can differ:
cocaine use among injecting drug users is rare in Indonesia
[20] and common in high-income settings. Side effects of
cocaine include stroke and myocardial infarction, which could
also contribute to the clinical endpoints. For these reasons,
CD4 cell decline is a more meaningful marker to investigate.
To our knowledge, this study is the first to show that IDU
accelerates CD4 cell decline in a low-income setting. Our
results support a study from McNeil et al. who used models
of HIV progression with a square root transformation of CD4
cell counts in a high-income setting (Scotland) [12]. Similar
to our cohort, 70% of patients in that study had a history of
IDU and 70% were male. Based on their study population,
the authors of that study created two models which both
showed that individuals infected through IDU tended to
have a faster CD4 cell decline than those infected through
heterosexual contact (p0.13 and 0.05) [12]. Other epide-
miological studies on HIV progression in drug users found
contradictory results [8,9,11,14,21]. For instance, men having
sex with men had a higher AIDS incidence compared to other
risk groups in a study using data from several cohorts.
However, this effect could be explained by the high incidence
of Kaposi sarcoma (often occurring at relatively higher CD4
cell counts) among men having sex with men [9]. Others
found that the use of drugs, especially heroin, was associated
with faster disease progression [11]. However, most studies
were conducted in high-income settings, which have a dif-
ferent distribution of opportunistic infections, such as tuber-
culosis. In addition, many studies used clinical endpoints
instead of CD4 cell counts, or other statistical methods, such
as Markov models and hazard ratios. Consequently, the
outcomes of these studies are somewhat difficult to compare
with our results.
Older age has been associated with faster disease pro-
gression in several studies [9,22,23]. However, in our patient
cohort the age range was small (IQR 2631 years), which
could explain why we did not find any association between
age and the natural CD4 cell decline (p0.312). HIV viral
replication is another variable that may influence the natural
decline of CD4 cells [8,24,25]. Plasma HIV RNA measure-
ments, only introduced recently in Indonesia [26], were not
associated with CD4 cell decline, and did not modify the
association between IDU and CD4 cell decline.
HIV tropism has been associated with HIV progression,
with faster CD4 cell decline and worse clinical outcome
associated with the X4 virus [21,27,28]. X4 viruses have been
found more often among recently infected injecting drug
users, which could be explained by preferential infection
of R5 virus through sexual intercourse [29,30]. However,
another study found that X4 viruses were not more common
among chronically infected drug users [29]. As we did not
determine HIV tropism in our study, we cannot exclude a
higher prevalence of X4 as a factor associated with faster CD4
cell decline.
Another possible explanation for the more rapid CD4 cell
decline among IDUs could be the high rate of co-infection
with HCV, as previous studies have shown deteriorated
clinical outcome among HIV-positive individuals with HCV
antibodies [3136]. Indeed, the Swiss Cohort study found
that both HCV seropositivity and IDU were independently
associated with clinical outcome of HIV [34]. However, the
relation between HCV infection and CD4 cell decline prior to
ART remains unclear, [3133,36,37] indeed the effects of
HCV seems to be more pronounced among patients receiving
ART [37,38]. In addition, no correlation has been reported
Table 3. The influence of other variables on the predicted CD4 cell decline
Variable Estimate p-value# AIC
Estimate
IDU*months2
p-Value
IDU*months2
Complete model* n.a. n.a. 677.8 0.00043 B0.001
Plasma HIV-RNA 0.0001 0.977 455.3 0.00041 B0.001
Gender 0.0014 0.915 675.8 0.00043 B0.001
Age 0.0011 0.274 676.9 0.00043 B0.001
Candida infection 0.0025 0.883 640.7 0.00043 B0.001
Hepatitis C antibodies 0.0055 0.764 571.0 0.00044 B0.001
All variables$ n.a. n.a. 385.0 0.00045 B0.001
# p-value of the change in the complete model (as described in Table 2) by adding the variable.
*Model as described in Table 2: Log (CD4 cell count)0.09640.9623*log (CD4 baseline)  0.0093*months  0.0083*IDU  0.0004*
IDU*months2.
$ Including all variables, namely plasma HIV-RNA, gender, age, Candida infection and hepatitis C antibodies, in the complete model.
Akaike information criterion (AIC) measures the relative goodness of fit of a statistical model; model with lowest AIC has the best fit.
n.a., not applicable.
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between HCV and CD4 cell apoptosis, as a possible explana-
tion for a more rapid CD4 cell decline [39]. In our study, the
high prevalence (89.6%) of HCV infection among injecting
drug users made it difficult to study the independent effect
of HCV.
Finally, immunomodulating effects of heroin and other
opioids could affect the CD4 cell decline. In vitro studies have
indeed shown that opioids increase the expression of the HIV
co-receptors CXCR4 and CCR5 and consequently increase
viral replication of HIV [26]. In addition, opioids could in-
fluence HIV-mediated apoptosis of both HIV-infected and
uninfected cells, which is considered an important cause
of CD4 cell decline during HIV infection. In neuronal cells,
morphine was shown to enhance HIV-induced apoptosis
[40,41]. Also in immune cells (peripheral blood mononuclear
cells), significantly more apoptosis was observed when cells
were exposed to morphine in combination with HIV protein
gp120 [42].
In this study, we only selected subjects with at least two
CD4 cell counts before initiating ART. Only 20% of our cohort
fits these criteria, since many patients come at a late stage of
disease and start ART soon after diagnosis. However, there
were no differences between individuals with and without
a history of IDU in terms of proportion of subjects included,
baseline characteristics and rates of loss to follow-up.
Therefore, it seems unlikely that the difference we found
in CD4 cell decline was due to selection bias. Also, patient
characteristics were comparable with those of the total
population, suggesting that our study population is repre-
sentative of patients diagnosed with HIV in this setting.
However, active drug users who are HIV positive (and who
might have a different prognosis) probably have lower access
to health services in Indonesia, and might therefore be
underrepresented. Overall, we believe selection bias within
the HIV clinic was limited, but we cannot exclude bias due to
differences in health seeking behaviour.
Conclusions
In conclusion, we have shown that IDU accelerates the
natural decline of CD4 cells in HIV patients in Indonesia.
In a recent study within the same cohort, we have found that
a history of IDU in HIV-positive patients does not have a
negative effect on virological or immunological response to
ART, nor on retention to treatment and mortality [18]. These
findings indicate that HIV disease progression should be
monitored carefully in injecting drugs users and that earlier
initiating of ART should be considered for this risk group.
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